These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 2788763)

  • 1. In vivo induction of interleukin-1 during hemodialysis.
    Haeffner-Cavaillon N; Cavaillon JM; Ciancioni C; Bacle F; Delons S; Kazatchkine MD
    Kidney Int; 1989 May; 35(5):1212-8. PubMed ID: 2788763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Production of cytokines in hemodialysis.
    Tetta C; Camussi G; Turello E; Salomone M; Aimo G; Priolo G; Segoloni G; Vercellone A
    Blood Purif; 1990; 8(6):337-46. PubMed ID: 2093331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokine production during hemodialysis: effects of dialytic membrane and complement activation.
    Lin YF; Chang DM; Shaio MF; Lu KC; Chyr SH; Li BL; Sheih SD
    Am J Nephrol; 1996; 16(4):293-9. PubMed ID: 8739281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ex vivo flow cytometry determination of intracytoplasmic expression of IL-2, IL-6, IFN-gamma, and TNF-alpha in monocytes and T lymphocytes, in chronic hemodialysis patients.
    Rostaing L; Peres C; Tkaczuk J; Charlet JP; Bories P; Durand D; Ohayon E; de Préval C; Abbal M
    Am J Nephrol; 2000; 20(1):18-26. PubMed ID: 10644863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Production and kinetics of interleukin-1 in hemodialysis. In vivo and in vitro study.
    Donati D; Degiannis D; Homer L; Raska K; Raskova J
    Am J Nephrol; 1991; 11(6):451-8. PubMed ID: 1819211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered interleukin-1 production in patients undergoing hemodialysis.
    Blumenstein M; Schmidt B; Ward RA; Ziegler-Heitbrock HW; Gurland HJ
    Nephron; 1988; 50(4):277-81. PubMed ID: 3266310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukocyte, platelet and endothelial activation in patients with acute renal failure treated by intermittent hemodialysis.
    de Sá HM; Freitas LA; Alves VC; Garção MF; Rosa MA; Marques AA
    Am J Nephrol; 2001; 21(4):264-73. PubMed ID: 11509797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of peripheral blood monocytes in haemodialysis: in vivo induction of tumour necrosis factor alpha, interleukin 6 and beta 2-microglobulin.
    Pertosa G; Marfella C; Tarantino EA; Di Cillo M; Manno C; Russo R; Schena FP
    Nephrol Dial Transplant; 1991; 6 Suppl 2():18-23. PubMed ID: 1866063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary report on complement activating potential of polycarbonate membrane.
    Henderson LW; Chenoweth DE; Shinaberger JH; Miller J; Konstantin P
    Blood Purif; 1986; 4(1-3):74-81. PubMed ID: 3730164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum interleukin-6 in long-term hemodialyzed patients.
    Cavaillon JM; Poignet JL; Fitting C; Delons S
    Nephron; 1992; 60(3):307-13. PubMed ID: 1565183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monocyte cell-surface CD14 expression and soluble CD14 antigen in hemodialysis: evidence for chronic exposure to LPS.
    Nockher WA; Scherberich JE
    Kidney Int; 1995 Nov; 48(5):1469-76. PubMed ID: 8544403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Normal T lymphocyte function in patients with end-stage renal disease hemodialyzed with 'high-flux' polysulfone membranes.
    Degiannis D; Czarnecki M; Donati D; Homer L; Eisinger RP; Raska K; Raskova J
    Am J Nephrol; 1990; 10(4):276-82. PubMed ID: 2240054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of ultrapure and non-sterile dialysate on the inflammatory response during in vitro hemodialysis.
    Tielemans C; Husson C; Schurmans T; Gastaldello K; Madhoun P; Delville JP; Marchant A; Goldman M; Vanherweghem JL
    Kidney Int; 1996 Jan; 49(1):236-43. PubMed ID: 8770974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-1 kinetics in hemodialysis.
    Donati D; Degiannis D; Homer L; Raska K; Raskova J
    ASAIO Trans; 1991; 37(3):M391-2. PubMed ID: 1751203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of IL-1 during hemodialysis: transmembrane passage of intact endotoxins (LPS).
    Laude-Sharp M; Caroff M; Simard L; Pusineri C; Kazatchkine MD; Haeffner-Cavaillon N
    Kidney Int; 1990 Dec; 38(6):1089-94. PubMed ID: 2127434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of vancomycin in patients undergoing hemodialysis with polyacrylonitrile.
    Torras J; Cao C; Rivas MC; Cano M; Fernandez E; Montoliu J
    Clin Nephrol; 1991 Jul; 36(1):35-41. PubMed ID: 1889149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes.
    Descamps-Latscha B; Herbelin A; Nguyen AT; Roux-Lombard P; Zingraff J; Moynot A; Verger C; Dahmane D; de Groote D; Jungers P
    J Immunol; 1995 Jan; 154(2):882-92. PubMed ID: 7814891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cuprophane haemodialysis induces upregulation of LPS receptor (CD14) on monocytes: role of complement activation.
    Marchant A; Tielemans C; Husson C; Gastaldello K; Schurmans T; De Groote D; Duchow J; Vanherweghem L; Goldman M
    Nephrol Dial Transplant; 1996 Apr; 11(4):657-62. PubMed ID: 8671854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apoptosis of monocytes cultured from long-term hemodialysis patients.
    Heidenreich S; Schmidt M; Bachmann J; Harrach B
    Kidney Int; 1996 Mar; 49(3):792-9. PubMed ID: 8648922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endotoxins modulate chronically tumour necrosis factor alpha and interleukin 6 release by uraemic monocytes.
    Pertosa G; Gesualdo L; Bottalico D; Schena FP
    Nephrol Dial Transplant; 1995; 10(3):328-33. PubMed ID: 7792027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.